KEI, HealthGap comments on NIH exclusive license to Precision IBD for patents on TLIA Antibodies
The below are comments were filed by KEI and HealthGap on May 22, 2018, regarding a proposed NIH exclusive license on patents for the treatment and diagnosis of Crohn’s Disease, Ulcerative Colitis, Asthma, Psoriasis and Biliary Cirrhosis to Precision IBD… Continue Reading